The proportion of patients with an objective response by BICR was higher with nivolumab plus chemotherapy (83 [53%] of 158 patients) versus chemotherapy (31 [20%] of 157 patients) in patients with tumor cell PD‐L1 ≥1% and in the overall population (152 [47%] of 321 and 86 [27%] of 324 patients) (Table 2). This evidence concerns the gene CD274 and neoplasm.